drugset
drugset / Trial / NCT06701149

A Comparative Study of the Pharmacokinetics of SIM0718 Injection in Healthy Adult Subjects in China

NCT06701149 ↗

Phase 1 Completed 178 enrolled Simcere Pharmaceutical Co., Ltd
RandomizedParallel-groupOpen-labelOther

Summary

A study to compare the pharmacokinetics, safety and immunogenicity of SIM0718 injection in healthy adult subjects in China

Timeline

Start
2024-11-28
Primary completion
2025-05-22
Completion
2025-05-22

Drugs

EvaluationDrugModalityDoseRoute
Comparator CBP-201 Unknown 300 mg Subcutaneous
Subject Rademikibart Monoclonal antibody 300 mg Subcutaneous

Indications

No indication recorded.